 |
PDBsum entry 1t49
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Allosteric inhibition of protein tyrosine phosphatase 1b
|
|
Structure:
|
 |
Protein-tyrosine phosphatase, non-receptor type 1. Chain: a. Fragment: residues 1-298. Synonym: protein-tyrosine phosphatase 1b, ptp-1b. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: ptpn1, ptp1b. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Resolution:
|
 |
|
1.90Å
|
R-factor:
|
0.207
|
R-free:
|
0.236
|
|
|
Authors:
|
 |
C.Wiesmann,K.J.Barr,J.Kung,J.Zhu,W.Shen,B.J.Fahr,M.Zhong,L.Taylor, M.Randal,R.S.Mcdowell,S.K.Hansen
|
Key ref:
|
 |
C.Wiesmann
et al.
(2004).
Allosteric inhibition of protein tyrosine phosphatase 1B.
Nat Struct Mol Biol,
11,
730-737.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
28-Apr-04
|
Release date:
|
20-Jul-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P18031
(PTN1_HUMAN) -
Tyrosine-protein phosphatase non-receptor type 1 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
435 a.a.
282 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.1.3.48
- protein-tyrosine-phosphatase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate
|
 |
 |
 |
 |
 |
O-phospho-L-tyrosyl-[protein]
|
+
|
H2O
|
=
|
L-tyrosyl-[protein]
|
+
|
phosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Nat Struct Mol Biol
11:730-737
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Allosteric inhibition of protein tyrosine phosphatase 1B.
|
|
C.Wiesmann,
K.J.Barr,
J.Kung,
J.Zhu,
D.A.Erlanson,
W.Shen,
B.J.Fahr,
M.Zhong,
L.Taylor,
M.Randal,
R.S.McDowell,
S.K.Hansen.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Obesity and type II diabetes are closely linked metabolic syndromes that afflict
>100 million people worldwide. Although protein tyrosine phosphatase 1B (PTP1B)
has emerged as a promising target for the treatment of both syndromes, the
discovery of pharmaceutically acceptable inhibitors that bind at the active site
remains a substantial challenge. Here we describe the discovery of an allosteric
site in PTP1B. Crystal structures of PTP1B in complex with allosteric inhibitors
reveal a novel site located approximately 20 A from the catalytic site. We show
that allosteric inhibitors prevent formation of the active form of the enzyme by
blocking mobility of the catalytic loop, thereby exploiting a general mechanism
used by tyrosine phosphatases. Notably, these inhibitors exhibit selectivity for
PTP1B and enhance insulin signaling in cells. Allosteric inhibition is a
promising strategy for targeting PTP1B and constitutes a mechanism that may be
applicable to other tyrosine phosphatases.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2. Crystal structures reveal a novel allosteric site in
PTP1B. (a) Inhibitor 2 (spheres) binds in a groove formed by
helices 3
and 6
that positions the catalytically important WPD loop. Distance
from the active site Cys is 20
Å. (b) Compound 2 binds in a hydrophobic pocket formed by
Leu192, Phe196 and Phe280. Hydrogen bonds with side chains of
Glu276, Asn193 and the main chain carbonyl of Phe196
(water-mediated) are shown. (c) Overlay of the crystal
structures of compounds 1 (orange, 2.2-Å resolution), 2 (yellow,
1.9-Å resolution) and 3 (blue sticks and mesh, 2.7 Å
resolution). The benzofuran core of the three compounds occupies
the same hydrophobic site. Allosteric inhibitors progressively
wrap around Phe280, correlating with increasing potency. PTP1B
and the side chain of Phe280 are gray. This figure was created
using PyMOL (DeLano Scientific; http://www.pymol.org).
|
 |
Figure 7.
Figure 7. The allosteric-bound conformation is similar to
conformations of PTP1B with the WPD loop in the open
conformation. (a) Overlay of 16 structures of PTP1B with the
WPD loop in the open conformation (black), along with PTP1B
bound to compound 2 (spheres, protein in magenta), and the
closed conformation (green, PDB entry 1PTY). Alignment shows
that the allosteric-bound conformation is similar to many open
conformations. (b) Allosteric inhibitor binds to the naturally
occurring open conformation (E[o]) of PTP1B and inhibits
activity by blocking closure of the WPD loop. Compound cannot
bind to the closed conformation.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nat Struct Mol Biol
(2004,
11,
730-737)
copyright 2004.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
E.Ferrari,
M.Tinti,
S.Costa,
S.Corallino,
A.P.Nardozza,
A.Chatraryamontri,
A.Ceol,
G.Cesareni,
and
L.Castagnoli
(2011).
Identification of new substrates of the protein-tyrosine phosphatase PTP1B by Bayesian integration of proteome evidence.
|
| |
J Biol Chem,
286,
4173-4185.
|
 |
|
|
|
|
 |
V.V.Vintonyak,
H.Waldmann,
and
D.Rauh
(2011).
Using small molecules to target protein phosphatases.
|
| |
Bioorg Med Chem,
19,
2145-2155.
|
 |
|
|
|
|
 |
C.Valmas,
M.N.Grosch,
M.Schümann,
J.Olejnik,
O.Martinez,
S.M.Best,
V.Krähling,
C.F.Basler,
and
E.Mühlberger
(2010).
Marburg virus evades interferon responses by a mechanism distinct from ebola virus.
|
| |
PLoS Pathog,
6,
e1000721.
|
 |
|
|
|
|
 |
K.C.Carver,
T.M.Piazza,
and
L.A.Schuler
(2010).
Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells.
|
| |
J Biol Chem,
285,
8003-8012.
|
 |
|
|
|
|
 |
L.Sylvest,
C.D.Bendiksen,
and
G.Houen
(2010).
Phosphatase inhibitors with anti-angiogenic effect in vitro.
|
| |
APMIS,
118,
49-59.
|
 |
|
|
|
|
 |
M.Na,
P.T.Thuong,
I.H.Hwang,
K.Bae,
B.Y.Kim,
H.Osada,
and
J.S.Ahn
(2010).
Protein tyrosine phosphatase 1B inhibitory activity of 24-norursane triterpenes isolated from Weigela subsessilis.
|
| |
Phytother Res,
24,
1716-1719.
|
 |
|
|
|
|
 |
R.A.Ward
(2010).
Using protein-ligand docking to assess the chemical tractability of inhibiting a protein target.
|
| |
J Mol Model,
16,
1833-1843.
|
 |
|
|
|
|
 |
V.S.Muthusamy,
C.Saravanababu,
M.Ramanathan,
R.Bharathi Raja,
S.Sudhagar,
S.Anand,
and
B.S.Lakshmi
(2010).
Inhibition of protein tyrosine phosphatase 1B and regulation of insulin signalling markers by caffeoyl derivatives of chicory ( Cichorium intybus) salad leaves.
|
| |
Br J Nutr,
104,
813-823.
|
 |
|
|
|
|
 |
D.Vidović,
and
S.C.Schürer
(2009).
Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design.
|
| |
J Med Chem,
52,
6649-6659.
|
 |
|
|
|
|
 |
M.D.Daily,
and
J.J.Gray
(2009).
Allosteric communication occurs via networks of tertiary and quaternary motions in proteins.
|
| |
PLoS Comput Biol,
5,
e1000293.
|
 |
|
|
|
|
 |
N.J.Beresford,
D.Mulhearn,
B.Szczepankiewicz,
G.Liu,
M.E.Johnson,
A.Fordham-Skelton,
C.Abad-Zapatero,
J.S.Cavet,
and
L.Tabernero
(2009).
Inhibition of MptpB phosphatase from Mycobacterium tuberculosis impairs mycobacterial survival in macrophages.
|
| |
J Antimicrob Chemother,
63,
928-936.
|
 |
|
|
|
|
 |
T.D.Bugg
(2009).
Oxygenases get to grips with polypeptides.
|
| |
Structure,
17,
913-914.
|
 |
|
|
|
|
 |
V.V.Vintonyak,
A.P.Antonchick,
D.Rauh,
and
H.Waldmann
(2009).
The therapeutic potential of phosphatase inhibitors.
|
| |
Curr Opin Chem Biol,
13,
272-283.
|
 |
|
|
|
|
 |
Y.Zhang,
Y.Li,
Y.W.Guo,
H.L.Jiang,
and
X.Shen
(2009).
A sesquiterpene quinone, dysidine, from the sponge Dysidea villosa, activates the insulin pathway through inhibition of PTPases.
|
| |
Acta Pharmacol Sin,
30,
333-345.
|
 |
|
|
|
|
 |
A.Bakan,
J.S.Lazo,
P.Wipf,
K.M.Brummond,
and
I.Bahar
(2008).
Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening.
|
| |
Curr Med Chem,
15,
2536-2544.
|
 |
|
|
|
|
 |
J.C.Juarez,
M.Manuia,
M.E.Burnett,
O.Betancourt,
B.Boivin,
D.E.Shaw,
N.K.Tonks,
A.P.Mazar,
and
F.Doñate
(2008).
Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling.
|
| |
Proc Natl Acad Sci U S A,
105,
7147-7152.
|
 |
|
|
|
|
 |
K.Bharatham,
N.Bharatham,
Y.J.Kwon,
and
K.W.Lee
(2008).
Molecular dynamics simulation study of PTP1B with allosteric inhibitor and its application in receptor based pharmacophore modeling.
|
| |
J Comput Aided Mol Des,
22,
925-933.
|
 |
|
|
|
|
 |
L.Tabernero,
A.R.Aricescu,
E.Y.Jones,
and
S.E.Szedlacsek
(2008).
Protein tyrosine phosphatases: structure-function relationships.
|
| |
FEBS J,
275,
867-882.
|
 |
|
|
|
|
 |
S.Liu,
L.F.Zeng,
L.Wu,
X.Yu,
T.Xue,
A.M.Gunawan,
Y.Q.Long,
and
Z.Y.Zhang
(2008).
Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors.
|
| |
J Am Chem Soc,
130,
17075-17084.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Del Sol,
M.J.Araúzo-Bravo,
D.Amoros,
and
R.Nussinov
(2007).
Modular architecture of protein structures and allosteric communications: potential implications for signaling proteins and regulatory linkages.
|
| |
Genome Biol,
8,
R92.
|
 |
|
|
|
|
 |
K.Fenn,
and
K.R.Matthews
(2007).
The cell biology of Trypanosoma brucei differentiation.
|
| |
Curr Opin Microbiol,
10,
539-546.
|
 |
|
|
|
|
 |
K.M.Picha,
S.S.Patel,
S.Mandiyan,
J.Koehn,
and
L.P.Wennogle
(2007).
The role of the C-terminal domain of protein tyrosine phosphatase-1B in phosphatase activity and substrate binding.
|
| |
J Biol Chem,
282,
2911-2917.
|
 |
|
|
|
|
 |
M.Stuible,
L.Zhao,
I.Aubry,
D.Schmidt-Arras,
F.D.Böhmer,
C.J.Li,
and
M.L.Tremblay
(2007).
Cellular inhibition of protein tyrosine phosphatase 1B by uncharged thioxothiazolidinone derivatives.
|
| |
Chembiochem,
8,
179-186.
|
 |
|
|
|
|
 |
R.Maccari,
P.Paoli,
R.Ottanà,
M.Jacomelli,
R.Ciurleo,
G.Manao,
T.Steindl,
T.Langer,
M.G.Vigorita,
and
G.Camici
(2007).
5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases.
|
| |
Bioorg Med Chem,
15,
5137-5149.
|
 |
|
|
|
|
 |
T.S.Girish,
and
B.Gopal
(2007).
The crystal structure of the catalytic domain of the chick retinal neurite inhibitor-receptor protein tyrosine phosphatase CRYP-2/cPTPRO.
|
| |
Proteins,
68,
1011-1015.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.Sun,
Q.Wang,
Z.Yu,
Y.Zhang,
Y.Guo,
K.Chen,
X.Shen,
and
H.Jiang
(2007).
Hyrtiosal, a PTP1B inhibitor from the marine sponge Hyrtios erectus, shows extensive cellular effects on PI3K/AKT activation, glucose transport, and TGFbeta/Smad2 signaling.
|
| |
Chembiochem,
8,
187-193.
|
 |
|
|
|
|
 |
X.Y.Zhang,
and
A.C.Bishop
(2007).
Site-specific incorporation of allosteric-inhibition sites in a protein tyrosine phosphatase.
|
| |
J Am Chem Soc,
129,
3812-3813.
|
 |
|
|
|
|
 |
A.J.Barr,
and
S.Knapp
(2006).
MAPK-specific tyrosine phosphatases: new targets for drug discovery?
|
| |
Trends Pharmacol Sci,
27,
525-530.
|
 |
|
|
|
|
 |
B.Szöor,
J.Wilson,
H.McElhinney,
L.Tabernero,
and
K.R.Matthews
(2006).
Protein tyrosine phosphatase TbPTP1: A molecular switch controlling life cycle differentiation in trypanosomes.
|
| |
J Cell Biol,
175,
293-303.
|
 |
|
|
|
|
 |
D.F.Lazar,
and
A.R.Saltiel
(2006).
Lipid phosphatases as drug discovery targets for type 2 diabetes.
|
| |
Nat Rev Drug Discov,
5,
333-342.
|
 |
|
|
|
|
 |
E.Asante-Appiah,
S.Patel,
C.Desponts,
J.M.Taylor,
C.Lau,
C.Dufresne,
M.Therien,
R.Friesen,
J.W.Becker,
Y.Leblanc,
B.P.Kennedy,
and
G.Scapin
(2006).
Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase.
|
| |
J Biol Chem,
281,
8010-8015.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.Montalibet,
K.Skorey,
D.McKay,
G.Scapin,
E.Asante-Appiah,
and
B.P.Kennedy
(2006).
Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding.
|
| |
J Biol Chem,
281,
5258-5266.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.S.Swaney,
H.H.Patel,
U.Yokoyama,
B.P.Head,
D.M.Roth,
and
P.A.Insel
(2006).
Focal adhesions in (myo)fibroblasts scaffold adenylyl cyclase with phosphorylated caveolin.
|
| |
J Biol Chem,
281,
17173-17179.
|
 |
|
|
|
|
 |
S.Yang,
M.K.Na,
J.P.Jang,
K.A.Kim,
B.Y.Kim,
N.J.Sung,
W.K.Oh,
and
J.S.Ahn
(2006).
Inhibition of protein tyrosine phosphatase 1B by lignans from Myristica fragrans.
|
| |
Phytother Res,
20,
680-682.
|
 |
|
|
|
|
 |
X.Hu,
and
C.E.Stebbins
(2006).
Dynamics of the WPD loop of the Yersinia protein tyrosine phosphatase.
|
| |
Biophys J,
91,
948-956.
|
 |
|
|
|
|
 |
C.Steegborn,
T.N.Litvin,
K.C.Hess,
A.B.Capper,
R.Taussig,
J.Buck,
L.R.Levin,
and
H.Wu
(2005).
A novel mechanism for adenylyl cyclase inhibition from the crystal structure of its complex with catechol estrogen.
|
| |
J Biol Chem,
280,
31754-31759.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.Buck,
H.Bourne,
and
J.A.Wells
(2005).
Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor.
|
| |
J Biol Chem,
280,
4009-4012.
|
 |
|
|
|
|
 |
S.Li,
R.S.Depetris,
D.Barford,
J.Chernoff,
and
S.R.Hubbard
(2005).
Crystal structure of a complex between protein tyrosine phosphatase 1B and the insulin receptor tyrosine kinase.
|
| |
Structure,
13,
1643-1651.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.A.Hardy,
J.Lam,
J.T.Nguyen,
T.O'Brien,
and
J.A.Wells
(2004).
Discovery of an allosteric site in the caspases.
|
| |
Proc Natl Acad Sci U S A,
101,
12461-12466.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |